Funding Plans - Oracle plans to secure between $45 billion and $50 billion in funding during 2026 to expand its cloud infrastructure capacity to meet demand from clients like AMD, Nvidia, Meta, OpenAI, TikTok, and xAI [1] - The funding will be raised through a combination of equity and debt financing, with an approximate split of 50% for each approach [1] Equity Financing - For the equity portion, Oracle will utilize a mix of equity-linked and common equity issuances, including an initial offering of mandatory convertible preferred securities and an at-the-market equity program authorized for up to $20 billion [2] - Shares will be issued under this program in line with market prices and capital requirements [2] Debt Financing - Oracle expects to complete a single issuance of investment-grade senior unsecured bonds early in 2026, with no additional bond offerings planned for the year beyond this transaction [3] - Goldman Sachs & Co. will lead the senior unsecured bond offering, while Citigroup will manage the at-the-market equity issuance and the convertible preferred equity offering [3] Strategic Goals - The funding approach aims to preserve Oracle's investment-grade rating and maintain balance sheet strength while expanding cloud services [4] - Oracle anticipates 2026 to be a pivotal year for advancing AI in the US, focusing on building AI infrastructure to support medical research, scientific breakthroughs, and economic growth [4] AI Infrastructure Development - Oracle is developing AI data center campuses in collaboration with OpenAI in Texas and other sites in New Mexico, Wisconsin, and Michigan, with a commitment to benefit local communities [5] - The company plans to fund on-site power generation or grid upgrades and implement closed-loop cooling systems to limit water use [5] AI Supercomputer Collaboration - In October 2025, Oracle and Nvidia collaborated to build an AI supercomputer named Solstice at Argonne National Laboratory for the US Department of Energy, achieving a combined output of 2,200 exaflops of AI performance [6]

Core Insights - Tesla is poised to become the largest global manufacturer of artificial intelligence chips according to CEO Elon Musk [1] - The company is restarting its AI supercomputer project to enhance its self-driving and robotics technology [1] Company Developments - Tesla's initiative to lead in AI chip production indicates a strategic focus on advancing its technological capabilities [1] - The revival of the AI supercomputer project suggests a commitment to improving the efficiency and effectiveness of its autonomous driving and robotics systems [1]

Core Insights - NVIDIA's market is experiencing significant growth, with a long-term outlook suggesting a valuation that is currently undervalued, trading at 40x earnings in early 2026, and potentially offering 200% to 500% gains over the next decade [3][4] Company Developments - NVIDIA has entered a $1 billion partnership with Eli Lilly to develop an AI supercomputer aimed at accelerating drug discovery and manufacturing processes, marking a significant expansion beyond its traditional GPU market [4][5] - The collaboration will utilize a loop-style system where AI-generated discoveries assist physicians, and in turn, physicians will enhance AI models, thereby transforming the drug discovery industry [5] Market Potential - The drug discovery market is valued at over $105 billion as of the end of 2025, with a projected high-single-digit growth rate of nearly 10% annually [6] - AI-enabled drug discovery currently represents less than 20% of the market but is expected to grow sixfold in the next eight years, indicating substantial future opportunities [6] - The drug discovery sector serves as a gateway to the more lucrative drug production and sales market, which exceeds $550 million in the US alone [6]

Core Insights - Recursion Pharmaceuticals owns the largest AI supercomputer in the pharmaceutical industry, aimed at accelerating drug development, but lacks market-ready products [1][4] - Eli Lilly is presented as a safer investment option, with a strong product portfolio and consistent revenue growth, while also planning to build a larger AI supercomputer [6][7] Group 1: Recursion Pharmaceuticals - Recursion Pharmaceuticals uses a proprietary operating system and AI algorithm to run virtual experiments, predicting effective compounds for specific diseases [3] - The company claims it can reduce the time and cost of drug development, but has not yet proven its effectiveness, with no products in the market or phase 3 studies [4] - Despite partnerships with major pharmaceutical companies like Merck and Roche, Recursion's research has not yielded significant results, making its stock appear risky [5] Group 2: Eli Lilly - Eli Lilly is a well-established pharmaceutical company with a growing revenue stream and a strong position in the weight loss market, making its future outlook attractive [6] - The company plans to build an AI supercomputer that will surpass Recursion's, utilizing its extensive data from past clinical trials to enhance its AI drug discovery models [7][8] - Eli Lilly's established market presence and data advantage make it a safer investment to capitalize on AI-driven drug discovery compared to Recursion Pharmaceuticals [7]

Core Insights - Recursion Pharmaceuticals is a small player in the biotech industry with potential upside in AI drug discovery [1] - The company utilizes AI to enhance drug development processes, aiming to improve success rates in clinical trials [3][5] - Recursion has established partnerships with major pharmaceutical companies, indicating the promise of its AI-based strategy [7][8] Group 1 - Recursion Pharmaceuticals employs AI to develop drugs, addressing the slow and costly nature of traditional drug development [3][4] - The company has built the largest supercomputer in the pharmaceutical industry in partnership with Nvidia, which may provide a competitive edge [5][6] - The FDA's shift towards AI-based testing methods could further benefit Recursion's approach [6] Group 2 - Recursion has formed partnerships with leading pharmaceutical companies such as Merck, Bayer, Sanofi, and Roche, which validate its AI strategy [7][8] - These partnerships contribute to the evidence supporting Recursion's approach, although the company has yet to achieve significant clinical success [9]

Core Insights - Global spending on AI is projected to reach nearly $1.5 trillion in 2023 and could exceed $2 trillion by 2026 [1] - Nvidia, with a market cap of $4.5 trillion, is a key player driving innovation in the AI sector [1] Company Partnerships - Nvidia has a long-standing partnership with OpenAI, dating back to 2016 when it delivered the first AI supercomputer to OpenAI [4][5] - The recent deal with OpenAI allows Nvidia to sell directly to them, marking a shift from previous cloud-based sales [6][7] - Nvidia's unique position in the market is highlighted by its ability to provide complete AI infrastructure, including CPUs, GPUs, networking chips, and software [7] Financial Dynamics - The partnership with OpenAI involves Nvidia potentially investing alongside other investors as OpenAI raises funds through revenues, equity, or debt [9] - Nvidia estimates that building AI factories will require about $50 to $60 billion for every gigawatt of capacity [8] Competitive Landscape - Nvidia's chips are described as special and superior, with the company emphasizing the need for a variety of chips to build effective AI supercomputers [14][15] - The competitive strategy of AMD, which involves giving away a significant stake in the company to partner with OpenAI, is viewed as surprising and risky [10][12] - Nvidia's ongoing innovation and optimization across its AI infrastructure are crucial for maintaining its competitive edge [15][16]

Core Insights - Nscale has raised USD $1.1 billion in Series B funding, marking the largest such round in UK and European history, led by Aker ASA with participation from notable investors including NVIDIA and Dell [2][9][12] Company Overview - Nscale is an AI-native infrastructure platform headquartered in the UK, providing integrated computing, networking, storage, and AI services through its own data centers [3][13] - The company addresses the increasing enterprise demand for GPUs, essential for AI, and operates data centers that utilize low-cost renewable energy [4][12] Funding Utilization - The new funding will facilitate the deployment of large-scale AI infrastructure across Europe, North America, and the Middle East, including the development of "AI factory" data centers for projects like Stargate UK and Stargate Norway [5][9] - The capital will also support the expansion of Nscale's engineering and operations teams to enhance service delivery for enterprise and government clients [5][12] Strategic Partnerships and Projects - Nscale has announced a partnership with Microsoft to develop the UK's largest AI supercomputer and is collaborating with OpenAI and NVIDIA on the Stargate UK project [9][11] - The company is also working on Stargate Norway, aiming to deliver 100,000 NVIDIA GPUs by the end of 2026, supported by a multi-billion-dollar agreement with Microsoft [11][12] Product Innovation - Nscale is accelerating product innovation across the AI stack, launching services such as fine-tuning, advanced inference APIs, and orchestration tools [8][12] Leadership and Vision - Nscale's leadership team has extensive experience in building data centers and scaling infrastructure businesses, positioning the company to meet the surging demand for AI infrastructure [7][12] - The company aims to create a globally significant platform to provide high-demand compute capacity and energy-efficient AI infrastructure [6][7]

Market Overview - Wall Street reached new record highs driven by the Federal Reserve's quarter-point interest rate cut and expectations of further reductions in upcoming meetings [2][8] - The S&P 500, Nasdaq, and Russell 2000 indices all achieved unprecedented levels, with technology stocks leading the gains [2][8] - Nvidia's $5 billion investment in Intel resulted in a significant 23.1% to 24.6% increase in Intel's shares, marking its largest daily gain since 1987 [2][8] Corporate Performance - FedEx reported a strong first quarter for fiscal year 2025, with adjusted earnings per share of $3.83, surpassing the estimated $3.59, and revenue of $22.2 billion, exceeding predictions of $21.67 billion [3][8] - The company's adjusted operating income reached $1.30 billion, higher than the expected $1.21 billion, indicating a robust start to the fiscal year [3] Capital Flows - U.S. Treasury International Capital (TIC) data for July showed a significant decline in net long-term capital inflows, totaling $49.2 billion, down from $150.8 billion in the same period last year [4][8] - Despite the monthly dip, total foreign holdings of U.S. Treasuries reached a record high of $8.339 trillion in July, up from $8.211 trillion in June [4][8] Geopolitical Developments - Former President Trump announced efforts to regain control of Afghanistan's Bagram Air Base, emphasizing its strategic importance due to its proximity to China's nuclear facilities [5][8] Technology Investments - Microsoft announced a $4 billion expansion of its data center investments in Wisconsin, bringing its total investment in the state to over $7 billion [6][8]